About Event

Since Kinase inhibitors have proven to be efficacious and approvable targets, fuelling recent investment into this exciting space as their therapeutic targeting is explored beyond oncology. However, increasing resistance to existing programs and safety bottlenecks threaten further progress. The next wave of kinase targets depends on innovation. 

Join the  2nd Next Generation Kinase Inhibitors Summit  to connect with experts across discovery, R&D, and clinical medicine to discuss how to accelerate the next generation of kinase inhibitor drugs to market, which displays maximal therapeutic efficacy and durable clinical responses. 

Key Topics:

https://kinase-inhibitors-summit.com/wp-content/uploads/sites/649/2021/11/cropped-CDD-2020-Home-Page-Banner-BELLA-8.png

 

Assay Development, Kinome Exploration & and Kinase-Focussed Drug Discovery Principles

https://kinase-inhibitors-summit.com/wp-content/uploads/sites/649/2021/11/cropped-CDD-2020-Home-Page-Banner-BELLA-8.png

Overcoming Tumor Resistance, Managing the Tumor Microenvironment, and Improving Durability

https://kinase-inhibitors-summit.com/wp-content/uploads/sites/649/2021/11/cropped-CDD-2020-Home-Page-Banner-BELLA-8.png

Exploiting the RAS/MAPK Signalling Pathway

https://kinase-inhibitors-summit.com/wp-content/uploads/sites/649/2021/11/cropped-CDD-2020-Home-Page-Banner-BELLA-8.png

Multikinase and Combination Therapies to Overcoming Resistance 

https://kinase-inhibitors-summit.com/wp-content/uploads/sites/649/2021/11/cropped-CDD-2020-Home-Page-Banner-BELLA-8.png

Targeting Established Pharmacological Mechanisms in Alternative Indications Beyond Oncology to Meet Unmet Needs